ライフサイエンスコーパス: transitional cell

1 ation of acinar cells to the nestin-positive transitional cell.

2 superficial endocardial layer of atrial and transitional cells.

3 artment, enriched for CXCL13-responsive late transitional cells.

4 of large-sized cells somewhat similar to the transitional cells.

5 band of well-polarized but poorly excitable transitional cells.

6 lls with AT2 and AT1 cell features, known as transitional cells.

7 er cells: Core Pacemaker, Sinus Venosus, and Transitional Cells.

8 d promoting the accumulation of VSMC-derived transitional cells.

9 ore readily proliferate and form KRT8/CLDN4+ transitional cells.

10 of integrated stress response (ISR) genes in transitional cells.

11 had reduced intercalated cells and increased transitional cells.

12 is higher than that of mesothelial cells and transitional cells.

13 iated with the appearance of nestin-positive transitional cells.

14 ls cause fibrosis, whether keratins regulate transitional cell accumulation and fibrosis, and why tra

15 events AT1 differentiation and leads to KRT8 transitional cell accumulation in progressive pulmonary

16 osis in a K8-dependent manner; in mice, most transitional cells and fibrosis resolved, whereas in hum

17 venting the uncontrolled accumulation of AT2 transitional cells and promoting AT1 differentiation.

18 native pathway, the survival of neonatal B-1 transitional cells and their maturation into B-1 B cells

19 of gene regulatory programs leading to Krt8+ transitional cells and their terminal differentiation to

20 lar B cells in splenic development, immature transitional cells are an essential component for unders

21 However, transitional cells are larger and have an overall less d

22 Some transitional cells are supporting cells participating in

23 High numbers of non-HLA-binding transitional cells associated with B-suppressed interfer

24 Fifteen patients with recurrent superficial transitional cell bladder carcinoma who experienced prio

25 ammary and prostate cancers, the majority of transitional cell bladder tumors showed Id1 protein expr

26 exhibits significant activity in metastatic transitional cell cancer with minimal toxicity, but surv

27 ificant risk factor for EN and its attendant transitional cell cancer.

28 ed EN, (ii) these adducts can be detected in transitional cell cancers, and (iii) A:T --> T:A transve

29 onstrated absent or greatly reduced pinin in transitional cell carcinoma (TCC) and RCC tumors.

30 y culture (P0) and after passage in vitro of transitional cell carcinoma (TCC) biopsies that represen

31 ghly tumorigenic and highly metastatic human transitional cell carcinoma (TCC) cell line 253J B-V ove

32 ltetrazolium bromide (MTT) assays in bladder transitional cell carcinoma (TCC) cell lines RT4 and SW7

33 and protein are observed among several human transitional cell carcinoma (TCC) cell lines, suggesting

34 GF) accumulates in the nucleus in aggressive transitional cell carcinoma (TCC) cells and this histolo

35 Human transitional cell carcinoma (TCC) cells are labeled with

36 ptor (BMP-R) types IA, IB, and II in bladder transitional cell carcinoma (TCC) cells.

37 IFN-alpha therapy for clinical treatment of transitional cell carcinoma (TCC) has prompted us to inv

38 Transitional cell carcinoma (TCC) is a pan-urothelial di

39 therapy surgery for patients with metastatic transitional cell carcinoma (TCC) is controversial.

40 Prostatic transitional cell carcinoma (TCC) is present in up to 48

41 Transitional cell carcinoma (TCC) of the bladder compris

42 of noninvasive methods for the diagnosis of transitional cell carcinoma (TCC) of the bladder remains

43 We have screened 193 cases of transitional cell carcinoma (TCC) of the bladder using 3

44 invasive method for monitoring patients with transitional cell carcinoma (TCC) of the bladder would b

45 q is the most frequent genetic alteration in transitional cell carcinoma (TCC) of the bladder, implic

46 e identify a potential role for proHB-EGF in transitional cell carcinoma (TCC) of the bladder.

47 ured biopsies of superficial and myoinvasive transitional cell carcinoma (TCC) of the bladder.

48 vement in the development and progression of transitional cell carcinoma (TCC) of the bladder.

49 9 are the most common genetic alteration in transitional cell carcinoma (TCC) of the bladder.

50 mine the relative levels of MSI and EMAST in transitional cell carcinoma (TCC) of the upper and lower

51 eleted in many human malignancies, including transitional cell carcinoma (TCC) of the urinary bladder

52 ations are known to be associated with human transitional cell carcinoma (TCC) of the urinary bladder

53 Our microRNA profiling of bladder transitional cell carcinoma (TCC) patient samples reveal

54 orifice positive for a high-grade papillary transitional cell carcinoma (TCC) with muscularis propri

55 on forms of bladder tumors: 69 of 97 (71.1%) transitional cell carcinoma (TCC), 38 of 53 (71.6%) squa

56 ividuals currently face a high prevalence of transitional cell carcinoma (TCC), a form of bladder can

57 Transitional cell carcinoma (TCC), a neoplasm of urinary

58 remains the standard of care for metastatic transitional cell carcinoma (TCC), but its limitations i

59 predominant component in the development of transitional cell carcinoma (TCC), but the particular pa

60 Transitional cell carcinoma (TCC), the most common cance

61 potential as an immunotherapeutic target in transitional cell carcinoma (TCC).

62 dies demonstrated chromosome 3p deletions in transitional cell carcinoma (TCC).

63 be well tolerated in patients with advanced transitional cell carcinoma (TCC).

64 proven modality for treatment of upper-tract transitional cell carcinoma (TCC).

65 invasive or high-grade recurrent superficial transitional cell carcinoma (TCC; lymph node-negative, 1

66 In the SCID-beige mice, T24 human bladder transitional cell carcinoma also was used as the tumor i

67 he current fund of knowledge about prostatic transitional cell carcinoma and the implications for dia

68 ntly it has been shown to be a human bladder transitional cell carcinoma cell line.

69 n of p27(Kip1) and cyclin E in human bladder transitional cell carcinoma cells correlates with advanc

70 chemotherapy in advanced upper urinary tract transitional cell carcinoma continue to evolve and remai

71 F-7, pancreatic carcinoma (CRL 1420, bladder transitional cell carcinoma EJ, and melanoma LOX) but no

72 The operative management of invasive transitional cell carcinoma has advanced significantly i

73 onsidered related to the study drug (bladder transitional cell carcinoma in the ozanezumab group and

74 ase 2 trial, we enrolled patients with T2-4a transitional cell carcinoma of the bladder at 24 medical

75 Patterns of RT112 cells derived from a transitional cell carcinoma of the bladder could be depo

76 Rb) expression was evaluated in 185 cases of transitional cell carcinoma of the bladder from patients

77 Transitional cell carcinoma of the bladder is a common m

78 Transitional cell carcinoma of the bladder is comprised

79 erin and interferon are clinically active in transitional cell carcinoma of the bladder, but their me

80 ir derived cell lines from two patients with transitional cell carcinoma of the bladder.

81 nti-Yo antibody response in association with transitional cell carcinoma of the bladder.

82 n a wide variety of human cancers, including transitional cell carcinoma of the bladder.

83 27(Kip1) and cyclin E, in the progression of transitional cell carcinoma of the bladder.

84 s the standard treatment for muscle-invasive transitional cell carcinoma of the bladder.

85 th bacille Calmette-Guerin (BCG) -refractory transitional cell carcinoma of the bladder.

86 Transitional cell carcinoma of the renal pelvis or dista

87 In a patient with transitional cell carcinoma of the renal pelvis, hydrone

88 We present four cases of transitional cell carcinoma of the transplant ureter (TC

89 rectomy has been the treatment of choice for transitional cell carcinoma of the upper urinary tract.

90 lear cell) renal carcinoma (11 of 11 cases), transitional cell carcinoma of the urinary bladder (6 of

91 ssue sections of canine spontaneous invasive transitional cell carcinoma of the urinary bladder (a mo

92 s accrued from patients with muscle-invasive transitional cell carcinoma of the urinary bladder (TCC-

93 COX-1 and COX-2 expression in human invasive transitional cell carcinoma of the urinary bladder by im

94 of chromosome 3 was conducted in 72 cases of transitional cell carcinoma of the urinary bladder using

95 n pet dogs with naturally occurring invasive transitional cell carcinoma of the urinary bladder.

96 oving the precision of the estimated risk of transitional cell carcinoma of the urinary tract associa

97 n of the bladder tumor and biopsy identified transitional cell carcinoma or urothelial carcinoma inva

98 Transitional cell carcinoma should be considered in pati

99 Treatment of T24 and transitional cell carcinoma TCC-SUP bladder cancer cells

100 Using a murine transitional cell carcinoma tumor model, MB49, which nat

101 We measured DNA methylation in 342 transitional cell carcinoma tumors at BCL2, PTGS2 (COX2)

102 Additionally, transitional cell carcinoma was observed in approximatel

103 % of the K5.COX-2 transgenic mice; no TCH or transitional cell carcinoma was observed in wild-type bl

104 of 31 consecutive patients with renal pelvic transitional cell carcinoma were evaluated.

105 Bladder cancer cell lines (J82, T24 and transitional cell carcinoma) significantly restored hepa

106 ickening in four patients (three of whom had transitional cell carcinoma), a renal abscess, a coloves

107 ses, 24 were renal cell carcinoma, one was a transitional cell carcinoma, and one was an angiomyolipo

108 Forty-three patients had transitional cell carcinoma, and six had squamous cell c

109 sing an early-stage renal cell carcinoma and transitional cell carcinoma, chronic lymphocytic leukemi

110 ancer, testis cancer and upper urinary tract transitional cell carcinoma, no recently published study

111 sic fibroblast growth factor (bFGF) in human transitional cell carcinoma, reduce its angiogenesis, an

112 identified as a region of non-random LOH in transitional cell carcinoma, suggesting the presence of

113 In transitional cell carcinoma, the most common form of bla

114 st described in 1991 for upper urinary tract transitional cell carcinoma, with long-term data now eme

115 inoma, adult polycystic kidney disease or in transitional cell carcinoma.

116 atment of organ-confined upper urinary tract transitional cell carcinoma.

117 Of patients with transitional-cell carcinoma (n = 776), LVI status was av

118 ed as an intravesical agent in patients with transitional-cell carcinoma (TCC) of the bladder.

119 d primarily patients with non-organ-confined transitional-cell carcinoma (TCC) of the bladder.

120 nd carboplatin for the treatment of advanced transitional-cell carcinoma (TCC) of the urothelium has

121 in previously treated patients with advanced transitional-cell carcinoma (TCC) of the urothelium.

122 patients with locally advanced or metastatic transitional-cell carcinoma (TCC) of the urothelium.

123 previously untreated patients with advanced transitional-cell carcinoma (TCC) to assess its efficacy

124 eported survival of patients with metastatic transitional-cell carcinoma (TCC) treated with systemic

125 icacy and toxicity in patients with advanced transitional-cell carcinoma (TCC) who had failed to resp

126 ymphadenectomy, with the intent to cure, for transitional-cell carcinoma of the bladder between July

127 Patients with measurable, locally advanced transitional-cell carcinoma of the bladder who were not

128 STT1, GSTM3, and GSTP1 in 1150 patients with transitional-cell carcinoma of the urinary bladder and 1

129 al urotoxicity, including the development of transitional-cell carcinoma of the urinary bladder.

130 Seven patients (5%) developed transitional-cell carcinoma of the urinary bladder.

131 ond-line treatment of patients with advanced transitional-cell carcinoma of the urothelial tract.

132 overall survival for patients with advanced transitional-cell carcinoma of the urothelium.

133 in patients with unresectable or metastatic transitional-cell carcinoma.

134 line therapy and emerging drugs for advanced transitional-cell carcinoma.

135 tment has an antitumor effect in superficial transitional-cell carcinoma.

136 y included 59 well-characterized superficial transitional cell carcinomas (Ta, n = 28; T1, n = 31) fo

137 pure squamous cell carcinomas (SCC), and in transitional cell carcinomas (TCC) of the bladder with S

138 five sarcomatoid RCC, two oncocytomas, three transitional cell carcinomas (TCC) of the renal pelvis a

139 FGFR3 coding sequence from 63 transitional cell carcinomas (TCC) of various stages and

140 elial carcinomas, including 28 pTa low-grade transitional cell carcinomas (TCC), 31 pTa high-grade TC

141 b and p53 pathway alterations in 12 invasive transitional cell carcinomas (TCCs) and addressed the fu

142 A survey of 50 transitional cell carcinomas (TCCs) revealed a UP-II pol

143 and nature of FGFR3 mutations in a panel of transitional cell carcinomas and cell lines and studied

144 PDE5 was overexpressed in human squamous and transitional cell carcinomas compared with normal urothe

145 ylation of four CpG islands in human urinary transitional cell carcinomas of different stages and gra

146 ed that around one-third (33/101) of primary transitional cell carcinomas of the bladder overexpress

147 More than 50% of transitional cell carcinomas of the bladder show loss of

148 ation of these genes by analyzing 69 primary transitional cell carcinomas of the bladder with a panel

149 but was detected in 25 of 29 (86%) invasive transitional cell carcinomas of the urinary bladder and

150 ity, we have studied a cohort of superficial transitional cell carcinomas of the urinary bladder by i

151 ed the pattern of allelic imbalance in human transitional cell carcinomas of the urinary bladder incl

152 NU plus H202 or H202 alone formed high-grade transitional cell carcinomas when injected into nude mic

153 g water and the incidence of urinary bladder transitional cell carcinomas.

154 microsatellite loci in 20 grade III invasive transitional cell carcinomas.

155 adder proliferative lesions, including three transitional cell carcinomas.

156 ssues and normal mammary tissues and bladder transitional cell carcinomas.

157 However, whether and how transitional cells cause fibrosis, whether keratins regu

158 Transitional cells, coexpressing hair cell and supportin

159 as defined by expression of alpha-SM actin) "transitional" cells, coexpressing both endothelial and S

160 "Transitional" cells, coexpressing both endothelial marke

161 identify ICAM1+NKX2-1+ progenitors as key transitional cells conserved in the developing human and

162 Putative ER(+)PR(+)CK5(+) transitional cells could be seen only in colonies or tum

163 ed >80 stem, progenitor, immune, stromal and transitional cells defined by distinctive surface marker

164 AEC1s without fibrosis in human ARDS and why transitional cells differentiate into AEC1s during physi

165 gulating AT2 cell self-renewal and promoting transitional cell differentiation into AT1 cells.

166 ly Walthard cell nests represent urothelial (transitional cell) differentiation.

167 d thymocytes paradoxically appear as CD4+8lo transitional cells during their differentiation into CD8

168 specimens, as well as 11 cases of low-grade transitional cell dysplasia, 21 cases of carcinoma in si

169 It is unknown whether transitional cells emerge and differentiate into AEC1s w

170 The transitional cells exhibit a similar apical-basal polari

171 mRNA was observed in proliferating oval and transitional cells, forming duct-like structures of cyto

172 TACI(+) transitional cells from BAFF-transgenic mice are charact

173 Patients with non-transitional-cell histology, poor performance status, an

174 a keratin 5 promoter, is sufficient to cause transitional cell hyperplasia (TCH) in 17% and 75% of th

175 hocytes are thought to develop from immature transitional cells in a BCR-dependent manner.

176 een proposed that these oval cells represent transitional cells in a nonhepatocytic liver facultative

177 the risk allele, due to an expansion of late transitional cells in a stage targeted by selection mech

178 eviously associated with dysplastic alveolar transitional cells in fibrotic lungs.

179 /or single-cell RNA sequencing revealed that transitional cells in mouse models of physiological rege

180 markers, suggest that CK19+/NCAM+ cells are transitional cells in the biliary lineage and that rare

181 ether, these results identify progenitor and transitional cells in the brown adipose lineage and defi

182 that are negative for all three markers are transitional cells in the hepatocytic lineage.

183 tinguished tumor populations from normal and transitional cells, including acinar-to-ductal metaplasi

184 layers, significantly increase the number of transitional cells, induce clustering of mitochondria an

185 onstrate that B-1 B cells are generated from transitional cell intermediates that emerge in a distinc

186 fatal early ARDS, AEC1 differentiation from transitional cells is incomplete, underlying persistent

187 but ongoing without fibrosis; senescence of transitional cells may be associated with pulmonary fibr

188 Akap12-/- prostate lobes suggests that these transitional cells may be the source of the lymph node m

189 Severe B-cell deficiency affects mature and transitional cells, mimicking the action of rituximab.

190 or, proHB-EGF, localizes to the cytoplasm of transitional cells of the human bladder urothelium and t

191 hway and allowing circus movement within the transitional cells of the posterior AV nodal connection.

192 w that, in contrast to the dependence of B-2 transitional cells on the alternative pathway, the survi

193 cells, suggesting that these newly generated transitional cells play a critical role in PD-1-based im

194 A transitional cell population, defined by the first downr

195 r ~2 wk after birth and then declines as B-2 transitional cells predominate.

196 gest that hFLMPCs are mesenchymal-epithelial transitional cells, probably derived from mesendoderm.

197 distinct treatment naive tumors, a papillary transitional cell renal cell carcinoma, a duodenal carci

198 Cases included 76 renal cell, 24 transitional cell renal pelvis and ureter, and 22 other

199 Transitional cells represent a crucial step in the diffe

200 ed, among the oval cells, a subpopulation of transitional cells showing features of maturing hepatocy

201 on programs that evolve through at least one transitional cell stage.

202 nto type-1 cells acquire pre-alveolar type-1 transitional cell state (PATS) en route to terminal matu

203 otes AT1 differentiation through action in a transitional cell state analogous to a transient interme

204 egulation of recently described iAT2-derived transitional cell state genetic markers.

205 d-type and mutant retinal cells, we reveal a transitional cell state of retinal progenitor cells (RPC

206 Transitional cell states are at the crossroads of crucia

207 Transitional cell states are critical in lung injury rep

208 A continuum of transitional cell states exists between these discrete s

209 fate conversion is mediated via distinctive transitional cell states of damage-associated transient

210 iment, MC offers a robust way to assay rare, transitional cell states that are pertinent to human dev

211 that the presence of unspliced mRNA reflects transitional cell states, informative for studies of dyn

212 e bacterial QIRs were harbored in underlying transitional cells, stimulation of epithelial turnover t

213 isthmal) zone of the gastric unit and become transitional cells (TCs) with molecular and ultrastructu

214 ated disks and gap junctions of Purkinje and transitional cells, telocytes, macrophages, endothelium,

215 clinically relevant but poorly characterized transitional cells that bridge the CCS and surrounding m

216 auses loss of parietal cells, development of transitional cells that express markers of mucus neck an

217 wly formed human B cells from bone marrow as transitional cells, they diverge along two developmental

218 ntative sample of normal and malignant human transitional cell tissues.

219 s of carcinoma in situ (CIS), 38 superficial transitional cell tumors (STCC, stages T(a)-T(1)), 65 mu

220 NA expression in two of five muscle-invasive transitional cell tumors when compared with normal sampl

221 that SHPCs may represent an intermediate or transitional cell type between oval cells and mature hep

222 A transitional cell type from the submesothelial cell phen

223 Transitional cells undergo extensive stretching during d

224 is regimen in patients with both TCC and non-transitional-cell urothelial tumors is ongoing.

225 renal failure and a strong association with transitional cell (urothelial) carcinoma of the upper ur

226 lear outer sulcus cells (OSC) and vestibular transitional cells (VTC) are part of the parasensory epi

227 Transitional cells were negative for principal cell and

228 acterized by a preponderance of immature and transitional cells, whose persistence was associated wit

229 n controls, and an increase in the number of transitional cells with a CD4+CD8low phenotype.

230 clustering structure for both pure cells and transitional cells with soft memberships.

231 mplete but ongoing AEC1 differentiation from transitional cells without fibrosis may underlie persist

232 g of postmortem ARDS lungs revealed abundant transitional cells without fibrosis.